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Introduction
As injured cardiac tissue cannot regenerate, patients
with ischaemic heart disease often develop heart 
failure. Since the onset of the concept of tissue engi-
neering [1], therapeutic strategies aimed at improv-
ing myocardial function via local stem cell delivery,
the so-called cellular cardiomyoplasty (CCM) are
viewed as a promising strategy for the treatment of
heart failure [2]. Different types of cells have been
investigated, but only bone marrow-derived stem
cells, endothelial progenitor cells and skeletal
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Abstract
In the post-infarcted heart, grafting of precursor cells may partially restore heart function but the improvement
is modest and the mechanisms involved remain to be elucidated. Here, we explored this issue by transplant-
ing C2C12 myoblasts, genetically engineered to express enhanced green fluorescent protein (eGFP) or
eGFP and the cardiotropic hormone relaxin (RLX) through coronary venous route to swine with experimen-
tal chronic myocardial infarction. The rationale was to deliver constant, biologically effective levels of RLX at
the site of cell engraftment. One month after engraftment, histological analysis showed that C2C12 myoblasts
selectively settled in the ischaemic scar and were located around blood vessels showing an activated
endothelium (ICAM-1-,VCAM-positive). C2C12 myoblasts did not trans-differentiate towards a cardiac phe-
notype, but did induce extracellular matrix remodelling by the secretion of matrix metalloproteases (MMP)
and increase microvessel density through the expression of vascular endothelial growth factor (VEGF).
Relaxin-producing C2C12 myoblasts displayed greater efficacy to engraft the post-ischaemic scar and to
induce extracellular matrix re-modelling and angiogenesis as compared with the control cells. By echocardio-
graphy, C2C12-engrafted swine showed improved heart contractility compared with the ungrafted controls,
especially those producing RLX. We suggest that the beneficial effects of myoblast grafting on cardiac function
are primarily dependent on the paracrine effects of transplanted cells on extracellular matrix remodelling and
vascularization. The combined treatment with myoblast transplantation and local RLX production may be help-
ful in preventing deleterious cardiac remodelling and may hold therapeutic possibility for post-infarcted patients.
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myoblasts have been employed in clinical trials [3–5].
Despite the studies showing that functional benefits
occur upon cell transplantation into the post-infarcted
heart [2], enthusiasm for CCM has been recently
tempered by controversy concerning the ability of the
grafted cells to re-constitute myocardial tissue
through trans-differentiation. Bone marrow stem cells
are unable to diverge from their lineage restriction
and adopt a cardiac phenotype [2, 5]. Skeletal
myoblasts also exhibit little or no tendency to shift to
a cardiac phenotype upon transplantation, as they
typically differentiate to myotubes that remain
embedded within the scar tissue, electrically and
functionally isolated from the recipient heart [6].
These observations suggest that the observed ben-
efits of CCM on heart contractility may depend on
indirect, paracrine actions of the grafted cells on the
post-infarcted heart, including angiogenesis and
extracellular matrix remodelling [2, 7]. This assump-
tion has gained support by recent findings that con-
ditioned medium from mesenchymal stem cells con-
tains pro-angiogenic factors and, when injected into
the post-infarcted heart, exerts cardiac protection
and induces functional recovery of the ischaemic
myocardium [8]. Decreased collagen deposition 
and reduced scar stiffness of the post-infarcted
myocardium can also contribute to the improvement
of myocardial compliance and contractility observed
after CCM [9], but the exact mediators responsible
for these effects are still unknown. A potential
approach to test this paracrine hypothesis is to com-
bine cell therapy with regional expression of relaxin
(RLX), a pleiotropic hormone best known for its
extracellular matrix-re-modelling properties (10).
RLX could be a good candidate, as it has multiple
effects on the cardiovascular system, including coro-
nary vasodilatation, neoangiogenesis, reduction of
heart fibrosis and protection against myocardial
ischaemia/reperfusion-induced injury [11–13].
Another key issue for the success of CCM is the
route of cell administration. The most commonly
used methods are the direct injection into the
myocardium or trans-coronary venous implantation
[5, 14]. However, these methods seem to favour the
generation of clusters of grafted cells which may act
as arrhythmogenic foci or produce myocardial
embolization [15]. In contrast, cell delivery by retro-
grade venous route using intracoronary catheters
offers several advantages over the other methods as
it represents a safer method to allow a homogeneous
settlement of the grafted cells into the post-infarcted
myocardium [5, 16].
The current study was designed to expand knowl-
edge on the potential mechanisms underlying the
functional benefits of cell transplantation on the post-
infarcted heart. C2C12 myoblasts, genetically engi-
neered to express enhanced green fluorescent pro-
tein (eGFP) or eGFP and RLX were transplanted by
retrograde coronary venous route to swine with
chronic myocardial infarction. The object was to
deliver constant, biologically effective levels of RLX
at the site of cell engraftment. We also investigated
the possible mechanisms involved.
Methods
Generation of C2C12 myoblast cell lines
Mouse skeletal C2C12 myoblasts (ATCC, Manassas, VA)
were cultured in DMEM containing 10% foetal bovine
serum (Sigma, Milan, Italy) Cells were transduced with a
lentiviral vector bicistronically expressing human preprore-
laxin 2 cDNA [17] and eGFP gene or just eGFP, under a
cytomegalovirus (CMV) promoter and termed C2C12/RLX
and C2C12/GFP, respectively. Day 2 supernatants from
C2C12/RLX cell cultures  contained 1.8±0.2 ng/ml RLX,
as assessed by a human H2 RLX-specific ELISA [17].
Clones were selected by cloning ring method and
analysed by fluorescent microscopy and flow cytometry for
eGFP expression.
Surgical treatments
The experimental protocol complied with the Declaration of
Helsinki and the recommendations of the European
Economic Community (86/609/CEE) on animal experimen-
tation. Male swine, 30–40 kg, underwent ligation of the left
anterior descending coronary artery after the 2nd diagonal
branch to induce myocardial infarction, as previously
described [13]. Thirty days after surgery, the animals were
re-operated and a balloon catheter was inserted through
the coronary sinus into the coronary vein draining the
infarcted area to inject the myoblasts, either C2C12/RLX or
C2C12/GFP (80 x 106 cells in 10–20 ml of culture medium),
by retrograde venous route. Control animals were injected
with cell-free culture medium. Cells or medium were inject-
ed over a 15-min period and the balloon catheter was kept
inflated for further 20 min. to favour cell settlement. All the
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transplanted animals underwent daily administration of
cyclosporine (1 mg/ kg b.wt.) and betamethasone (0.1 mg/kg
b.wt.) to obtain immune-suppression and anti-inflammatory
effects to enhance grafting chances of the heterologous
cells. The same treatment was also administered to the
untransplanted controls. They were housed for a further 30
days and then sacrificed. At autopsy, cardiac tissue sam-
ples taken 1–2 cm downstream the coronary occlusion
were taken for biochemical and morphological analyses.
Overall, mortality upon induction of myocardial infarction
was about 30%. The experiment was terminated when
each group comprised five animals. The levels of RLX
yielded by the above cell grafting protocol were measured
in plasma, isolated from peripheral blood, and cardiac tis-
sue extracts taken  at sacrifice from swine injected with
C2C12/RLX using a commercial human H2 RLX ELISA kit
(Immundiagnostik, Bensheim, Germany). Untransplanted
swine and animals receiving C2C12/GFP were used as
controls. To this end, the tissue samples, 50 mg each, were
minced and homogenized in cold lysis buffer composed 
by (mmol/l): Tris/HCl pH 7.4 10, NaCl 10, MgCl2 1.5,
Na2EDTA 2, phenylmethylsulfonyl fluoride (PMSF) 1, 
Triton X-100 (1%), Leupeptin (20 µg/ml), Pepstatin 
(1 µg/ml), Pefabloc (1 mg/ml), Aprotinin (2.5 µg/ml).
Upon centrifugation at 13,000 g for 10 min. at 4°C, 
the supernatants were collected and kept frozen at -20°C
until needed.
Confocal immunofluorescence
Cryostat sections, 10 µm thick, were cut from frozen tissue
samples, fixed in paraformaldehyde vapours for 10 min.
and incubated with the following antibodies: rhodamine-
conjugated mouse monoclonal anti-eGFP (Santa Cruz,
CA; 1:200); mouse monoclonal anti- sarcomeric actin
(Dako, Milan, Italy; 1:100); rabbit polyclonal anti-VCAM-1
(Santa Cruz; 1:100); mouse monoclonal anti-ICAM-1
(Chemicon, Temecula, CA; 1:200). When needed, immune
reaction was revealed by Alexa 488-conjugated antimouse
or antirabbit secondary antibodies (1:50; Molecular Probes,
Eugene, OR). Negative controls were performed with non-
immune mouse serum substituted for the primary antibody.
Cells were examined with a Bio-Rad 1024 confocal laser
scanning microscope (Bio-Rad, Hercules, California, USA)
equipped with a Krypton/Argon laser for fluorescence
measurements and differential interference contrast optics
for transmission images. Series of optical sections at inter-
vals of 0.4 µm were taken and superimposed as a single
image. In each animal, GFP-positive cells were counted on
five microscopical fields, 32,400 µm2, containing at least
one vascular profile. The numbers from two different
observers were then averaged.
Ultrastructure of cardiac tissue 
Cardiac tissue samples were fixed in glutaraldehyde-osmi-
um tetroxide, embedded in epoxy resin and routinely
processed for transmission electron microscopy. Some
fragments, not osmium-fixed, were used for immunoelec-
tron microscopy to detect RLX in the grafted C2C12/RLX
cells. Ultra-thin sections were etched with 30% hydrogen
peroxide and incubated with normal goat serum (Sigma;
1:20) to quench non-specific binding sites, then with rabbit
polyclonal anti-H2 RLX antibodies (Immundiagnostik; 10
µg/ml) and finally with goat antirabbit antibodies conjugat-
ed with 5 nm colloidal gold particles (BBInternational,
Stanstead, UK; 1:20). Negative controls were sections in
which non-immune rabbit serum was substituted for the pri-
mary antiserum. The sections were counterstained with
uranyl acetate and lead citrate and examined under a Jeol
1010 (Jeol, Tokyo, Japan) electron microscope at 80 kV.
Determination of fibrosis
Fibrosis in the cardiac scar was studied by qualitative and
quantitative morphological methods on paraformaldehyde-
fixed, paraffin-embedded samples. Sections 8 µm thick
were stained with Van Gieson method for collagen (fuchsin
0.1% in H2O containing 0.08% HCl for 4 min., followed by
5-min. rinsing in 95% ethanol). Five microscopical fields per
animal were registered by a digitizing camera applied to a
light microscope with a 20 x objective, each field corre-
sponding to a test area of 141,100 µm2. On the digitized
images, measurements of overall surface area (SA) and
optical density (OD) of the collagen fibres were carried out
using the Scion Image Alpha 4.0.3.2 image analysis pro-
gram (Scion Corp., Frederick, Maryland, USA), upon
appropriate threshold to exclude amorphous ground sub-
stance. For each animal, a sclerosis index was calculated
by the formula: SA x OD x 10-6. Values from the five ani-
mals in each group were then averaged.
Matrix metalloprotease activity in 
cardiac tissue and C2C12 myoblasts
Assay for matrix metalloprotease (MMP)/collagenase activ-
ity was performed by gelatin zymography assay. Primary
cultures of cardiac cells from the post-infarcted scar were
obtained by incubating the minced tissue with collagenase
II (250 IU/ml) in Hank's balanced salt solution, pH 7.4, for
40 min. at 37°C. Cells were filtered, plated in DMEM 
growing medium on 12-well multiplates and used at pas-
sages 0–1. By this procedure, the cells obtained were mainly
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fibroblasts and endothelial cells (data not shown). The car-
diac cells were co-cultured with myoblasts (C2C12/RLX or
C2C12/GFP) for 72 hrs in serum-free DMEM at a approx.
3:1 ratio. As controls, primary cardiac cells treated or not
with 1.8 ng/ml recombinant H2 RLX (Connetics Co., Palo
Alto, California, USA), and subconfluent C2C12/RLX and
C2C12/GFP cells were analysed after 72 hrs culture. The
conditioned medium was then collected and centrifuged at
10,000 x g for 15 min. In some experiments zymography
assay was performed on lysates obtained from the post-
infarcted myocardium of control and transplanted animals.
The tissue was homogenized in cold buffer containig 5 mM
Tris-HCl, 320 mM sucrose, 1 mM dithiothreitol, 10 µg/ml
leupeptin, 10µg/ml soybean inhibitor, 2 µg/ml aprotinin.
Tissue homogenates were centrifuged at 10,000 rpm for
10 min. at 4°C and then the supernatant used for zymogra-
phy assay. Protein content was measured in cell and tissue
lysates by the bicinchoninic acid method. Samples of con-
ditioned medium, 10 µl each, or of tissue (150 µg)  were
mixed with sample buffer (0.03% bromophenol blue, 0.4 mol/l
Tris-HCl pH 7.4, 20% glycerol, 5% SDS) and separated on
10% SDS-polyacrylamide gels containing gelatin (1 mg/ml).
After electrophoresis, gels were washed for 1 hrs in re-nat-
uration buffer (2.5% Triton X-100 in bidistilled water) and
subsequently incubated for 4 hrs at 37°C in 50 mmol/l Tris,
200 mmol/l NaCl and 5 mmol/l CaCl2, pH 7.5. Gels were
stained with 0.05% Coomassie Brilliant Blue and destained
with 30% methanol and 10% acetic acid; clear zones with-
in the background indicated proteolytic activity. MMPs were
identified by comparison with the respective recombinant
protein (Calbiochem-Novabiochem) and molecular weight
standards. Quantification was performed by densitometry
(QuantityOne software, Bio-Rad).
Determination of microvessel density
The volume density of microvessels in the cardiac scar tis-
sue was measured by point counting on semi-thin sections
of resin-embedded samples. Ten microscopical fields per
animal were registered by the same device described above
using a 20 x objective. A single square grid, with distance
between intersection points = 30 µm on the section, was
superimposed on each image. Test points corresponding to
the SA of microvessels were then counted. Measurements
performed by two independent observers were averaged.
VEGF expression in cardiac tissue
VEGF gene expression in the post-infarcted myocardium
were investigated on frozen samples by reverse transcrip-
tion-PCR (RT-PCR). Total RNA was extracted from
homogenized tissue using Trizol (Gibco-BRL) and quanti-
fied spectrophotometrically at 260-nm wavelength. Total
RNA (700 µg) was reverse-transcribed and amplified with
SuperScript One-StepTM RT-PCR System (Invitrogen,
Groningen, NL). cDNA was synthesized for 30 min. at
55°C, pre-denatured for 2 min. at 94°C and subjected to 35
cycles of PCR performed at 94°C for 15 sec., 57.3°C for 30
sec. and 72°C for 1 min.; the final extension step was per-
formed at 72°C for 5 min. Internal standards were generat-
ed by amplifying -actin mRNA (annealing temperature:
55°C). The following primers were used: mouse VEGF
(GenBank: M95200.1): forward 5'-CAGGCTGCTGTAAC-
GATGAA-3', reverse 5'-TTTCTCCGCTCTGAACAAGG-3';
porcine VEGF (GenBank: NM_214084.1): forward 5'-
AGGAGTACCCCGATGAGATC-3', reverse 5'-GGGATTTT-
CTTGCCTCGCTC-3'; porcine -actin (GenBank:
NM_031144): forward 5'-CCAACCGTGAAAAGATGACC-
3', reverse 5'-AGAGGTCTTTACGGATGTCA-3'. Expected
length of amplified fragments were 202, 200 and 539 base
pairs for mouse VEGF, porcine VEGF and -actin, respec-
tively. PCR products were electrophoresed on a 2%
agarose gel and stained with ethidium bromide.
Assessment of cardiac function
To evaluate ventricular contractile function, the animals
underwent trans-thoracic Doppler echocardiography using
a Philip EN/Visor C echocardiograph equipped with a 3.5
MHz phased array transducer. Analysis was carried out at
3 time points: before surgery; 1 month after myocardial
infarction immediately prior to cell injection; 1 month after
cell transplantation. The following parameters were evaluat-
ed: left ventricular end-diastolic and end-systolic diameters
(LVEDD and LVESD; expressed as mm), ejection fraction
(EF; expressed as percentage), according to Simpson's
method, and myocardial performance index (MPI), calculat-
ed as the ratio between the sum of isovolumetric contraction
and relaxation times and the ejection time [18, 19].
Statistical analysis
Values are means ± SEM of the five animals per group.
Unless otherwise stated, differences between the experi-
mental groups were evaluated by one-way ANOVA and
Newman-Keuls post-test. Calculations were made with
Prism 4 (GraphPad, San Diego, CA) statistical program.
Results
Morphological analysis of myoblast
homing to the post-infarcted myocardium
By confocal immunofluorescence, numerous GFP-
immunoreactive cells, either C2C12/GFP or
J. Cell. Mol. Med. Vol 11, No 5, 2007
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C2C12/RLX, were found in the scar tissue from the
transplanted groups but not in the control group (Fig.
1A–C). Their myoblastic nature was confirmed by
positive staining for a sarcomeric actin (Fig. 1D).
C2C12/GFP-injected hearts contained a lower num-
ber of immunoreactive cells compared with
C2C12/RLX-injected hearts (40 ± 7 versus 83 ± 12
cells/microscopical field; Student's t-test: P<0.01).
The engrafted cells were preferentially located
around blood vessels or in their close proximity and
were almost absent in the peri-infarcted, viable
myocardium. Interestingly, a clear-cut endothelial
expression of ICAM-1 and VCAM (Fig. 1E and F) was
detected in small-sized blood vessels within the post-
infarcted zone, but not in the non-ischaemic
myocardium (Fig. 1G), suggesting a role for activated
endothelium of the injured regions in myoblast
extravasation and homing. Immunoelectron
microscopy of hearts transplanted with C2C12/RLX
revealed the presence of RLX-producing cells in the
Fig. 1 (A–D) Merged confocal fluo-
rescence and differential interference
contrast images of sections from con-
trol (A), C2C12/GFP-transplanted (B)
and C2C12/RLX-transplanted (C, D)
hearts. Sections were stained with
anti-GFP antibodies (red) to identify
the engrafted myoblasts and counter-
stained with Syto3 (green) to reveal
nuclei (A–C). In (D), the sections were
stained with antibodies against the
skeletal muscle-specific isoform of  a-
sarcomeric actin. Myoblast-injected
hearts show immunoreactive cells in
the post-infarcted zone (B–D), mainly
located around blood vessels (aster-
isks) and scattered within the extracel-
lular matrix. No labelled cells can be
detected in the controls. C2C12/RLX-
implanted hearts contain significantly
more GFP-immunoreactive cells than
the C2C12/GFP-implanted ones.
(E–G) Confocal micrographs of sec-
tions from C2C12/RLX-treated hearts,
immunostained for V-CAM (E) and
ICAM (F, G). Both molecules (green)
are expressed by endothelial cells of
microvessels in the post-infarcted
zones (E, F); by contrast, no ICAM
staining is observed in the surround-
ing viable myocardium. Nuclei are
counterstained with propidium iodide
(red). Bars = 20 µm.
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Fig. 2 Immunoelectron micrographs of C2C12 myoblasts grafted in the post-infarcted heart, immunostained with anti-RLX anti-
bodies (revealed by 5 nm gold particles). In the upper panel, a C2C12/RLX myoblast shows clear-cut cytoplasmic RLX
immunoreactivity (details in the insets). In the lower panel, a C2C127GFP myoblast shows no immunolabelling (detail of the RER
area in the inset). Both cells show a discontinuous basement membrane (arrows) and are surrounded by a loose extracellular
matrix. Bar = 0.5 µm.
J. Cell. Mol. Med. Vol 11, No 5, 2007
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post-infarction area, containing RLX gold labelling
(Fig. 2). As expected, RLX-immunoreactive cells
were not found in the hearts transplanted with
C2C12/GFP (Fig. 2). The engrafted myoblasts could
be distinguished by the activated fibroblasts in the
scar because they showed a discontinuous base-
ment membrane and lack collagen microfibrils
apposed to the plasma membrane typical of fibrob-
lasts (compare with Fig. 3D). However, the injected
myoblasts remained single elements with no tenden-
cy to fuse into multinucleated myotubes, which were
never observed in the scar tissue  (Figs. 1 and 2).This
finding suggests that C2C12 myoblasts are unable to
regenerate contractile tissue at the grafting site, at
least in the current experimental conditions.
Extracellular matrix remodelling 
and microvessel density in the 
post-infarcted myocardium 
By Van Gieson staining, collagen fibres markedly
accumulated in the post-infarcted myocardium of the
control animals and were reduced in the transplant-
ed groups, especially in C2C12/RLX-treated animals
(Fig. 3A and C). Notably, ventricular tissue samples
Fig. 3 Upper panels. Light micro-
graphs of sections from  control (A),
C2C12/GFP- (B) and C2C12/RLX-
transplanted hearts (C), stained with
Van Gieson for collagen. A marked
reduction of the extent of fibrosis can
be seen in the ischaemic scars of the
myoblast-transplanted hearts; of note,
fibrosis is particularly attenuated in the
hearts receiving C2C12/RLX cells. Bar
= 20 µm. Centre panel. Sclerosis index
(optical x volume density of collagen
fibres) in the post-infarcted myocardi-
um, estimated by computer-aided mor-
phometry; (a) P<0.05 versus controls;
(b) P<0.001 versus controls; (c)
P<0.001 versus C2C12/GFP. Lower
panels. Electron micrographs of fibrob-
lasts from control (D) C2C12/GFP- (E)
and C2C12/RLX-transplanted hearts
(F). In the control, collagen microfibrils
form large bundles adjacent to the
cell’s plasma membrane (inset), as
occurs during de novo fibre assembly;
in the C2C12/GFP-transplanted
hearts, and even more in the
C2C12/RLX-transplanted ones, colla-
gen microfibrils are scattered and
loosely arranged. Bar = 0.5 µm.
1094 © 2007 The Authors
Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
coming from the post-infarcted areas were very sim-
ilar in histological appearance among the animals of
each group. Morphometric analysis of tissue collagen
content confirmed the visual observation (Fig. 3). By
electron microscopy, fibroblasts from the control
hearts featured activated cells, with cytoplasms filled
with protein synthesizing organelles and surrounded
by collagen bundles (Fig. 3D). Conversely, in the
hearts receiving C2C12/RLX, fibroblasts were
immersed in a loose extracellular matrix with few, thin
collagen fibrils (Fig. 3E). We then analysed MMP/
collagenase activity in tissue homogenates from the
post-infarction scar, as well as in primary cultures 
of swine cardiac cells incubated together with
C2C12/GFP or C2C12/RLX. MMP-2 activity was 
very low in the control hearts, whereas it was signifi-
cantly increased in the hearts containing grafted
C2C12/GFP and C2C12/RLX cells (P<0.01). We also
observed a tendency of C2C12/RLX-grafted hearts
to possess higher MMP-2 activity compared to the
C2C12/GFP ones, although the differences did not
reach statistical significance. On the other hand, we
found that both the co-cultures released collagen-
degrading enzymes in the supernatants, with signifi-
cantly higher levels in those containing C2C12/RLX
cells (Fig. 4). Of interest, both resident cardiac cells
and myoblasts contributed to MMP activity and this
effect was significantly enhanced by exogenous or
endogenous RLX (Fig. 4). Finally, we studied scar tis-
sue vascularization. In C2C12/GFP-transplanted
hearts, microvessel density was slightly but signifi-
cantly increased compared to the control group,
while it reached the highest values in C2C12/RLX
transplanted hearts (Fig. 5). Interestingly, changes in
microvascular density paralleled with porcine VEGF
mRNA expression in the cardiac scar (Fig. 5). Indeed,
VEGF mRNA was absent in control hearts, absent or
only slightly expressed in C2C12/GFP-injected hearts
and well detectable in the C2C12/GFP-injected
hearts (Table 1). On the other hand, C2C12-derived
mouse VEGF transcript was not detected in the spec-
imens from transplanted animals (data not shown),
suggesting that the engrafted myoblasts do not play a
substantial contribution to local VEGF production.
Fig. 4 Upper panel. Matrix metallopro-
tease (MMP) activity evaluated by gel-
atin zymography on cardiac tissue
samples from control (n=2, optical
density: 36±1), C2C12/GFP-trans-
planted (n=2, optical density: 92±4)
and C2C12/RLX-transplanted swine
(n=4, optical density: 106±13). Centre
and lower panel. MMP activity on con-
ditioned media from: primary cultures
of swine cardiac cells co-cultured with
C2C12/GFP (1) or C2C12/RLX
myoblasts (2), primary cultures of
swine cardiac cells incubated with
medium (3) or with H2 RLX (4),
C2C12/GFP (5) and C2C12/RLX
myoblasts (6). Densitometric analysis
of MMP activity, expressed as arbitrary
optical density units normalized to pro-
tein content. Molecular weights of the
collagen lysis bands are consistent
with MMP-9 and MMP-2. Transfection
or treatment with RLX preferentially
up-regulated MMP 2 activity. (a),
P<0.05 versus the co-cultures of car-
diac cells and C2C12/GFP; (b) P<0.05
versus the counterparts without RLX;
(c) P<0.05 versus cardiac cells treated
with exogenous RLX.
J. Cell. Mol. Med. Vol 11, No 5, 2007
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Plasma and cardiac tissue levels of RLX
By a specific ELISA assay for H2 RLX, no detectable
levels of the hormone were found in either blood or
tissue samples from untransplanted controls and
C2C12/GFP-treated animals. In the swine given
C2C12/RLX myoblasts, RLX was detected, although
at very low levels (85±12.3 pg/ml), in the post-infarct-
ed cardiac tissue but not in blood.
Cardiac function after cell transplantation
We finally investigated whether myoblast grafting
could improve the heart contractile performance by
Doppler echocardiography. Under basal conditions,
the animals of all groups showed similar values of
MPI, EF and left ventricular diameters (Fig. 6). One
month after myocardial infarction, the post-infarcted
area had a comparable extension in all the animal
groups and involved anteroseptal mid and apical
segments. Paradoxical motion occurred in two ani-
mals, whereas akinesia was observed in all the
remaining animals. MPI, which is inversely related to
ventricular functional impairment, as well as LVEDD
Fig. 5 Upper and centre panels. Light
micrographs of the microvascular net-
work in control (A), C2C12/GFP- (B)
and C2C12/RLX-transplanted hearts
(C), and morphometric assessment of
microvascular density. Both C2C12/
GFP- and C2C12/RLX-injected hearts
exhibit higher microvascular density
than the control hearts. Of note,
C2C12/RLX-injected hearts show sig-
nificantly higher microvascular density
than C2C12/GFP-injected ones. (a)
P<0.05 versus control; (b) P<0.01 ver-
sus control; (c) P<0.05 versus C2C12/
GFP. Lower panel. RT-PCR assay for
porcine VEGF transcripts in scar tissue
samples from controls (lanes 1, 2),
C2C12/GFP- (lanes 3,4) and C2C12/
RLX-transplanted hearts (lanes 5, 6).
Images are representative of five 
different animals per experimental
groups. Porcine VEGF mRNA is
absent in the control samples, is slight-
ly expressed in one of the two samples
of C2C12/GFP-injected hearts, and
clearly detectable in both the samples
from C2C12/RLX-injected hearts.
Table 1 VEGF mRNA expression in post-infarction cardiac
scar tissue
Animal No. Controls C2C12/GFP C2C12/RLX
1 - - ++
2 - + +++
3 - - ++
4 - - +++
5 - - +
Semi-quantitative evaluation of the intensity of the bands of RT-
PCR amplicons for porcine VEGF.
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and LVESD were markedly increased, whereas EF
was significantly decreased compared with the basal
values (Fig. 6). One month after cell transplantation,
MPI was markedly improved, EF was increased and
LVEDD and LVESD were slightly reduced in both the
transplanted groups as compared with the controls.
Fig. 6 Myocardial performance index (MPI), ejection fraction (EF), left ventricular end-diastolic and end-systolic diameters (LVEDD,
LVESD) evaluated in basal conditions (black bars), 1 month after the induction of myocardial infarction (post-AMI; striped bars) and
1 month after cell transplantation (post-cellular cardiomyoplasty [CCM]; open bars). Myoblast implantation improves cardiac func-
tion. C2C12/RLX myoblasts are more effective than C2C12/GFP ones. Significance of differences (one-way ANOVA): MPI: (a)
P<0.001 versus basal; (b) P<0.001 versus post-AMI; (c) P<0.01 versus controls; (d) P<0.001 versus controls; (e) P<0.05 versus
C2C12/GFP. EF: (a) P<0.01 versus basal; (b) P<0.001 versus post-AMI; (c) P<0.001 versus controls. LVEDD: (a) P<0.05 versus
basal; (b) P<0.01 versus basal; (c) P<0.01 versus controls. LVESD: (a) P<0.01 versus basal & post-AMI; (b) P<0.05 versus con-
trols; (c) P<0.001 versus controls.
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Notably, MPI in C2C12/RLX-treated hearts was sig-
nificantly lower than in the C2C12/GFP-treated
group, whereas the other parameters assayed were
also improved, although the values did not reach sta-
tistical significance with only five animals per group
(Fig. 6). Collectively, these data indicate that implant-
ed C2C12 cells attenuated ventricular dysfunction
after myocardial infarction and suggest that
C2C12/RLX cells are more effective in improving car-
diac performance.
Discussion
The present study has shown that transplanted
skeletal myoblasts produce increased vasculariza-
tion, promote collagen turnover and reduce fibrosis,
thereby improving left ventricular function. These
effects appear more prominent when myoblasts over-
expressing RLX were used. This study has also
underlined the importance of paracrine effects of
grafted cells in explaining cardiac functional improve-
ment and demonstrates the efficacy of retrograde
venous injection of cells in a large animal model that
fairly reproduces the human clinical conditions [5].
This study confirms previous findings with myoblasts
with one major difference; the myoblasts were inject-
ed 1 month after the induction of myocardial infarc-
tion, thus reproducing a more likely clinical scenario
than the injection of cells immediately after injury, as
done in most previous studies [2–4].
The use of transplanted cells over-producing car-
diotropic factors is particularly relevant in considera-
tion of the healing mechanisms involved in the post-
infarcted heart, which include a cascade of interwov-
en events such as inflammation, cardiomyocyte
demise and formation of fibrous scar [20]. These
changes increase the mechanical and functional
stress on the heart resulting in deterioration of car-
diac performance and deleterious ventricular remod-
elling. Recently, stem cell-based myocardial regener-
ation has been viewed as a potential therapeutic tool
for post-ischaemic dysfunction and many studies
have claimed improved cardiac function and attenua-
tion of adverse remodelling upon CCM (2–5).
Theoretically, two distinct mechanisms might be
involved in the ability of the grafted cells to sustain
cardiac contraction: trans-differentiation of progenitor
cells into myocardial and/or vascular tissues and
secretion of soluble factors exerting paracrine effects
on the host tissue.We show here that myoblast trans-
plantation improves the function of post-infarcted
hearts through paracrine pathways, consisting main-
ly in attenuation of collagen fibre deposition and
increase in the microvascular network in the
ischaemic scar. The functional benefits of myoblast
transplantation, especially using genetically engi-
neered RLX-producing cells, were properly shown by
the improvement of the echocardiographic indexes
and parameters of cardiac performance observed in
the transplanted animals. In particular, the utility of
MPI  in predicting left ventricular  functional outcome
has been demonstrated in a large cohort of  patients
with myocardial infarction [21] and it has been shown
to closely reproduce functional contractile parame-
ters measured using invasive catheter-based meth-
ods [18, 19].
The present findings confirm and extend the
results from previous studies on the ability of trans-
planted cells to exert pro-angiogenetic and cardio-
protective actions on the ischaemic myocardium and
contribute to the idea that other mechanisms inde-
pendent of myocardial trans-differentiation may
improve cardiac function [8, 22]. In particular, we
found that injection of C2C12 myoblasts via the ret-
rograde venous route in post-infarcted swine hearts
provided a selective dissemination of the cells within
the injured tissues. Since these cells were mainly
located around small blood vessels showing a  per-
missive endothelium (i.e. expressing endothelial
adhesion molecules such as ICAM-1 and VCAM), we
suggest that factors controlling the inflammatory
process in the post-infarcted myocardium [23] may
also guide myoblast extravasation from the blood.
Indeed, it has been previously shown that circulating
stem cells selectively migrate to the ischaemic
regions of the heart [24]. In our study, the engrafted
myoblasts failed to trans-differentiate into contractile
myocardium, in keeping with previous reports [6].
Instead, their presence within the fibrotic area was
associated with a remarkable loosening of the extra-
cellular matrix and increase in tissue microvascular
density, indicating that these cells were able to mod-
ify the elastic and trophic properties of the post-
infarcted myocardium. Noteworthy, the concept of
using myoblasts as carriers for RLX provided addi-
tional benefits to the post-infarction repair compared
with myoblasts alone, due to the superior ability of
C2C12/RLX to engraft the ischaemic hearts, re-model
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collagen and affect microvessel behaviour. This is in
agreement with previous studies showing that RLX is
a potent anti-fibrotic agent, capable to reduce the
extent of fibrosis and induce extracellular matrix
remodelling in various organs, including the heart
[10, 12, 25]. The use of RLX-producing cells may
have some advantages over the use of exogenously
administered RLX, consisting mainly in the possibili-
ty to obtain local, constant and biologically effective
levels of this hormone in the remodelling heart. In
this way, RLX may synergize with other paracrine
factors released in situ by the grafted myoblasts.
Changes in extracellular matrix composition in the
evolving infarction may change the physical proper-
ties of the scar and lead to better ventricular compli-
ance reduced myocardial stress and overall improve-
ment of cardiac function. Several lines of evidence
converge towards this interpretation: (i ) mesenchy-
mal cell injection into acute ischaemic myocardium
reduces ventricle dilatation affecting the fibrotic
microenviroment and elastic properties of the infarct-
ed area [9]; (ii ) inhibition of monocyte chemoattrac-
tant protein-1 attenuates post-infarction myocardial
failure by decreasing cardiac fibrosis [26]; and (iii )
skeletal myoblasts infused into the injured myocardi-
um elicit collagen remodelling within the infarcted
zones [16]. Increased microvessel density in the
post-infarcted cardiac scar may provide additional
benefits to matrix re-modelling, contributing to the
creation of a more favourable microenviroment capa-
ble of improving grafted cell survival, reducing scar
stiffness and preventing cardiomyocyte apoptosis in
the peri-infarction myocardium. This may also con-
tribute to explain the higher number of engrafted
C2C12/RLX compared with the C2C12/GFP
observed in the present study. However, a direct role
of RLX in sustaining cell viability cannot be ruled out,
but this issue would require additional study.
It has to be pointed out that, in our study, grafting
of C2C12/RLX myoblasts did not result in detectable
circulating levels of RLX, thus leading us to exclude
possible systemic effects of this hormone. Of note,
RLX has been reported to have significant angio-
genic and anti-fibrotic effects only in diseased organs
and tissues, leaving normal targets unaffected [27, 28].
The paradigm of a paracrine protection of post-
infarcted myocardium by the grafted cells is further
supported by the observation that C2C12/GFP
myoblasts and more effectively C2C12/RLX cells
were able to up-regulate MMP activity and VEGF
expression in cardiac cells. MMPs are involved in
extracellular matrix turnover, both in physiological
conditions or in response to inflammatory stimuli
[29]. They also play a role in myoblast migration and
fusion during muscle development and regeneration
[30], inflammatory cell invasion of the infarcted
myocardium during early healing [31], and post-
infarction ventricle re-modelling and dilatation [32].
On this basis, MMP activation and subsequent atten-
uation of scar stiffness may also explain the greater
engraftment potential of C2C12/RLX myoblasts as
compared with C2C12/GFP.
VEGF is a key promoter of angiogenesis and has
a straightforward role in CCM. In fact, VEGF gene
transfer enhances the efficacy of CCM in animal
models of chronic myocardial infarction [33, 34], and
intramyocardial injection of mesenchymal stem cells
results in up-regulation of tissue VEGF expression
associated with improved cardiac perfusion and con-
tractility [35]. In our study, the levels of VEGF tran-
scripts in the cardiac scar correlated well with the
grade of microvascular density, as it was higher in
C2C12/RLX-injected hearts which showed a more
extended vascular network. These findings are con-
sistent with the known vascular properties of RLX,
capable to induce coronary vasodilatation, sustain
coronary flow, and induce de novo angiogenesis and
VEGF expression [11, 25, 27].
In conclusion, our study suggests that the
improvement of cardiac function after myoblast trans-
plantation into post-infarcted myocardium mainly
relies on paracrine actions of the donor cells rather
than on myocardial trans-differentiation. These
effects appear to depend on local diffusible factors,
namely MMP and VEGF, capable to influence stiff-
ness and vascularization of the ischaemic scar. It
also suggests that genetically modified, RLX-produc-
ing cells can behave as an intrinsic RLX source in the
ischaemic myocardium capable to substantially
improve the benefits of myoblast transplantation.
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